Glycyx was founded by scientists and an experienced management team that has built multiple successful life science companies. Our lead candidate, axelopran, blocks a fundamental injury response pathway to increase immune infiltration of the tumor microenvironment (TME) and maintain effector phenotype, reducing tumor growth and preventing T-cell exhaustion. Immune potentiation is selectively targeted to the TME, avoiding systemic immune side effects